Details of the Drug

General Information of Drug (ID: DML60TN)

Drug Name
Sotalol
Synonyms
Sotalolum; Darob mite; Sotalol Monohydrochloride; Beta-Cardone; Betapace (TN); Betapace AF (TN); Darob mite (TN); MJ-1999; Sotacor (TN); Sotalex (TN); Sotalol (INN); Sotalol [INN:BAN]; Sotalolum [INN-Latin]; D,l-Sotalol; N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide; N-(4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}phenyl)methanesulfonamide; N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide; Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-(9CI); 4'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide; 4'-(1-Hydroxy-2-isopropylaminoethyl)methanesulfonanilid
Indication
Disease Entry ICD 11 Status REF
Sinus rhythm disorder BC9Y Approved [1], [2]
Therapeutic Class
Antiarrhythmic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 272.37
Topological Polar Surface Area (xlogp) 0.2
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability
The bioavailability of drug is 90-100% [4]
Clearance
The renal clearance of drug is 4.99 +/- 1.43 L/h [4]
Elimination
80-90% of a given dose is excreted in the urine as unchanged sotalol [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 10 - 20 hours [4]
Metabolism
The drug is not metabolised [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 19.56906 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.62% [6]
Vd
The volume of distribution (Vd) of drug is 1.2-2.4 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 137 mg/mL [3]
Chemical Identifiers
Formula
C12H20N2O3S
IUPAC Name
N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide
Canonical SMILES
CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O
InChI
InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3
InChIKey
ZBMZVLHSJCTVON-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5253
ChEBI ID
CHEBI:63622
CAS Number
3930-20-9
DrugBank ID
DB00489
TTD ID
D04VMT
VARIDT ID
DR00905
INTEDE ID
DR1501
ACDINA ID
D00636

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-1 (ADRB1) TTR6W5O ADRB1_HUMAN Antagonist [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Sotalol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Sotalol and Ivosidenib. Acute myeloid leukaemia [2A60] [38]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Sotalol and Midostaurin. Acute myeloid leukaemia [2A60] [38]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Sotalol and Idarubicin. Acute myeloid leukaemia [2A60] [38]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Sotalol and Daunorubicin. Acute myeloid leukaemia [2A60] [38]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Sotalol and Arn-509. Acute myeloid leukaemia [2A60] [38]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Sotalol and Gilteritinib. Acute myeloid leukaemia [2A60] [38]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Sotalol and Oliceridine. Acute pain [MG31] [38]
Scopolamine DMOM8AL Moderate Antagonize the effect of Sotalol when combined with Scopolamine. Addictive disorder [6C50-6C5Z] [39]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Sotalol and Metronidazole. Amoebiasis [1A36] [40]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Sotalol and Ivabradine. Angina pectoris [BA40] [39]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Sotalol and Bepridil. Angina pectoris [BA40] [38]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Sotalol and Dronedarone. Angina pectoris [BA40] [38]
Nifedipine DMSVOZT Moderate Increased risk of cardiac depression by the combination of Sotalol and Nifedipine. Angina pectoris [BA40] [41]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Sotalol and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [38]
Hydroxyzine DMF8Y74 Major Increased risk of prolong QT interval by the combination of Sotalol and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [38]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Sotalol and Cilostazol. Arterial occlusive disease [BD40] [38]
Voriconazole DMAOL2S Major Increased risk of prolong QT interval by the combination of Sotalol and Voriconazole. Aspergillosis [1F20] [38]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Sotalol and Posaconazole. Aspergillosis [1F20] [38]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Sotalol and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [38]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Sotalol and Desipramine. Attention deficit hyperactivity disorder [6A05] [38]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Sotalol and Ofloxacin. Bacterial infection [1A00-1C4Z] [42]
Ciprofloxacin XR DM2NLS9 Major Increased risk of prolong QT interval by the combination of Sotalol and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [42]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Sotalol and Clarithromycin. Bacterial infection [1A00-1C4Z] [38]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Sotalol and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [38]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Sotalol and Sparfloxacin. Bacterial infection [1A00-1C4Z] [42]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Sotalol and Gemifloxacin. Bacterial infection [1A00-1C4Z] [42]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Sotalol and Norfloxacin. Bacterial infection [1A00-1C4Z] [42]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Sotalol and Levofloxacin. Bacterial infection [1A00-1C4Z] [42]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Sotalol and Lomefloxacin. Bacterial infection [1A00-1C4Z] [42]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Sotalol and Telithromycin. Bacterial infection [1A00-1C4Z] [43]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Sotalol and Retigabine. Behcet disease [4A62] [38]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Sotalol and Cariprazine. Bipolar disorder [6A60] [44]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Sotalol and Loperamide. Bowel habit change [ME05] [45]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Sotalol and Eribulin. Breast cancer [2C60-2C6Y] [38]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Sotalol and Lapatinib. Breast cancer [2C60-2C6Y] [38]
Tamoxifen DMLB0EZ Major Increased risk of prolong QT interval by the combination of Sotalol and Tamoxifen. Breast cancer [2C60-2C6Y] [38]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Sotalol and Toremifene. Breast cancer [2C60-2C6Y] [38]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Sotalol and Bosutinib. Breast cancer [2C60-2C6Y] [38]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Sotalol and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [38]
Oxaliplatin DMQNWRD Major Increased risk of prolong QT interval by the combination of Sotalol and Oxaliplatin. Colorectal cancer [2B91] [38]
Atracurium DM42HXN Moderate Additive neuromuscular blocking effects by the combination of Sotalol and Atracurium. Corneal disease [9A76-9A78] [46]
Mivacurium DM473VD Moderate Additive neuromuscular blocking effects by the combination of Sotalol and Mivacurium. Corneal disease [9A76-9A78] [46]
Levobupivacaine DM783CH Moderate Increased risk of atrioventricular block by the combination of Sotalol and Levobupivacaine. Corneal disease [9A76-9A78] [47]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Sotalol and Halothane. Corneal disease [9A76-9A78] [38]
Pancuronium DMB0VY8 Moderate Additive neuromuscular blocking effects by the combination of Sotalol and Pancuronium. Corneal disease [9A76-9A78] [46]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Sotalol and Propofol. Corneal disease [9A76-9A78] [48]
Tubocurarine DMBZIVP Moderate Additive cardiorespiratory depression effects by the combination of Sotalol and Tubocurarine. Corneal disease [9A76-9A78] [46]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Sotalol and Sevoflurane. Corneal disease [9A76-9A78] [38]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Sotalol and Probucol. Coronary atherosclerosis [BA80] [38]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Sotalol and Clofazimine. Crohn disease [DD70] [38]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Sotalol and Mifepristone. Cushing syndrome [5A70] [38]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Sotalol and Pasireotide. Cushing syndrome [5A70] [38]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Sotalol and Osilodrostat. Cushing syndrome [5A70] [38]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Sotalol and Sertraline. Depression [6A70-6A7Z] [38]
Trimipramine DM1SC8M Major Increased risk of prolong QT interval by the combination of Sotalol and Trimipramine. Depression [6A70-6A7Z] [38]
Nortriptyline DM4KDYJ Major Increased risk of prolong QT interval by the combination of Sotalol and Nortriptyline. Depression [6A70-6A7Z] [38]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Sotalol and OPC-34712. Depression [6A70-6A7Z] [44]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Sotalol and Clomipramine. Depression [6A70-6A7Z] [38]
Trazodone DMK1GBJ Major Increased risk of prolong QT interval by the combination of Sotalol and Trazodone. Depression [6A70-6A7Z] [38]
Amoxapine DMKITQE Major Increased risk of prolong QT interval by the combination of Sotalol and Amoxapine. Depression [6A70-6A7Z] [38]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Sotalol and Doxepin. Depression [6A70-6A7Z] [38]
Mepenzolate DM8YU2F Moderate Antagonize the effect of Sotalol when combined with Mepenzolate. Digestive system disease [DE2Z] [39]
Oxybutynine DMJPBAX Moderate Antagonize the effect of Sotalol when combined with Oxybutynine. Discovery agent [N.A.] [39]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Sotalol and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [38]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Sotalol and Deutetrabenazine. Dystonic disorder [8A02] [38]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Sotalol and Ingrezza. Dystonic disorder [8A02] [38]
Ethacrynic acid DM60QMR Moderate Increased risk of ventricular arrhythmias by the combination of Sotalol and Ethacrynic acid. Essential hypertension [BA00] [49]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Sotalol and Phenoxybenzamine. Essential hypertension [BA00] [50]
Nicardipine DMCDYW7 Moderate Increased risk of cardiac depression by the combination of Sotalol and Nicardipine. Essential hypertension [BA00] [41]
Benzthiazide DMQWZ0H Moderate Increased risk of hyperglycemia by the combination of Sotalol and Benzthiazide. Essential hypertension [BA00] [49]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Sotalol and Solifenacin. Functional bladder disorder [GC50] [38]
Tolterodine DMSHPW8 Moderate Antagonize the effect of Sotalol when combined with Tolterodine. Functional bladder disorder [GC50] [39]
Pentamidine DMHZJCG Major Increased risk of prolong QT interval by the combination of Sotalol and Pentamidine. Fungal infection [1F29-1F2F] [38]
Propantheline DM2EN6G Moderate Antagonize the effect of Sotalol when combined with Propantheline. Gastric ulcer [DA60] [40]
Cimetidine DMH61ZB Moderate Decreased metabolism of Sotalol caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [51]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Sotalol and Cisapride. Gastro-oesophageal reflux disease [DA22] [38]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Sotalol and Sunitinib. Gastrointestinal stromal tumour [2B5B] [38]
Chlorothiazide DMLHESP Moderate Increased risk of hyperglycemia by the combination of Sotalol and Chlorothiazide. Heart failure [BD10-BD1Z] [49]
Furosemide DMMQ8ZG Moderate Increased risk of hyperglycemia by the combination of Sotalol and Furosemide. Heart failure [BD10-BD1Z] [49]
Bumetanide DMRV7H0 Moderate Increased risk of ventricular arrhythmias by the combination of Sotalol and Bumetanide. Heart failure [BD10-BD1Z] [49]
Hydroflumethiazide DMVPUQI Moderate Increased risk of hypertriglyceridemia by the combination of Sotalol and Hydroflumethiazide. Heart failure [BD10-BD1Z] [49]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Sotalol and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [38]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Sotalol and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [38]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Sotalol and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [52]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Sotalol and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [38]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Sotalol and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [38]
Levamlodipine DM92S6N Moderate Increased risk of cardiac depression by the combination of Sotalol and Levamlodipine. Hypertension [BA00-BA04] [41]
Doxazosin DM9PLRH Moderate Additive hypotensive effects by the combination of Sotalol and Doxazosin. Hypertension [BA00-BA04] [50]
Verapamil DMA7PEW Major Increased risk of cardiac depression by the combination of Sotalol and Verapamil. Hypertension [BA00-BA04] [41]
Indapamide DMGN1PW Moderate Increased risk of hyperglycemia by the combination of Sotalol and Indapamide. Hypertension [BA00-BA04] [49]
Trichlormethiazide DMHAQCO Moderate Increased risk of ventricular arrhythmias by the combination of Sotalol and Trichlormethiazide. Hypertension [BA00-BA04] [49]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of hyperglycemia by the combination of Sotalol and Hydrochlorothiazide. Hypertension [BA00-BA04] [49]
Clevidipine butyrate DMW4M97 Moderate Increased risk of cardiac depression by the combination of Sotalol and Clevidipine butyrate. Hypertension [BA00-BA04] [41]
Belladonna DM2RBWK Moderate Antagonize the effect of Sotalol when combined with Belladonna. Infectious gastroenteritis/colitis [1A40] [39]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Sotalol and Propiomazine. Insomnia [7A00-7A0Z] [44]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Sotalol and ITI-007. Insomnia [7A00-7A0Z] [44]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Sotalol and Polyethylene glycol. Irritable bowel syndrome [DD91] [53]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Sotalol and Phenolphthalein. Irritable bowel syndrome [DD91] [38]
Clidinium DMUMQZ0 Moderate Antagonize the effect of Sotalol when combined with Clidinium. Irritable bowel syndrome [DD91] [39]
Dicyclomine DMZSDGX Moderate Antagonize the effect of Sotalol when combined with Dicyclomine. Irritable bowel syndrome [DD91] [39]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Sotalol and Crizotinib. Lung cancer [2C25] [38]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Sotalol and Ceritinib. Lung cancer [2C25] [38]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Sotalol and Osimertinib. Lung cancer [2C25] [38]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Sotalol and Selpercatinib. Lung cancer [2C25] [38]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Sotalol and Lumefantrine. Malaria [1F40-1F45] [40]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Sotalol and Halofantrine. Malaria [1F40-1F45] [54]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Sotalol and Chloroquine. Malaria [1F40-1F45] [38]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Sotalol and Hydroxychloroquine. Malaria [1F40-1F45] [38]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Sotalol and Primaquine. Malaria [1F40-1F45] [38]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Sotalol and Arsenic trioxide. Mature B-cell lymphoma [2A85] [55]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Sotalol and Vemurafenib. Melanoma [2C30] [38]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Sotalol and LGX818. Melanoma [2C30] [38]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Sotalol and Panobinostat. Multiple myeloma [2A83] [38]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Sotalol and Thalidomide. Multiple myeloma [2A83] [40]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Sotalol and Romidepsin. Mycosis fungoides [2B01] [38]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Sotalol and Nilotinib. Myeloproliferative neoplasm [2A20] [38]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Sotalol and Dasatinib. Myeloproliferative neoplasm [2A20] [38]
Dimenhydrinate DM264B3 Moderate Increased risk of prolong QT interval by the combination of Sotalol and Dimenhydrinate. Nausea/vomiting [MD90] [40]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Sotalol and Promethazine. Nausea/vomiting [MD90] [38]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Sotalol and Granisetron. Nausea/vomiting [MD90] [38]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Sotalol and Dolasetron. Nausea/vomiting [MD90] [38]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Sotalol and Ondansetron. Nausea/vomiting [MD90] [38]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Sotalol and Entrectinib. Non-small cell lung cancer [2C25] [38]
Metolazone DMB39LO Moderate Increased risk of hyperglycemia by the combination of Sotalol and Metolazone. Oedema [MG29] [49]
Polythiazide DMCH80F Moderate Increased risk of hyperglycemia by the combination of Sotalol and Polythiazide. Oedema [MG29] [49]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Sotalol and Levomethadyl Acetate. Opioid use disorder [6C43] [39]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Sotalol and Lofexidine. Opioid use disorder [6C43] [38]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Sotalol and Rucaparib. Ovarian cancer [2C73] [38]
Dextropropoxyphene DM23HCX Major Increased risk of prolong QT interval by the combination of Sotalol and Dextropropoxyphene. Pain [MG30-MG3Z] [38]
Prilocaine DMI7DZ2 Moderate Increased risk of atrioventricular block by the combination of Sotalol and Prilocaine. Pain [MG30-MG3Z] [47]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Sotalol and Buprenorphine. Pain [MG30-MG3Z] [38]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Sotalol and Triclabendazole. Parasitic worm infestation [1F90] [38]
Biperiden DME78OA Moderate Antagonize the effect of Sotalol when combined with Biperiden. Parkinsonism [8A00] [39]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Sotalol and Pimavanserin. Parkinsonism [8A00] [38]
Apomorphine DMX38HQ Major Increased risk of prolong QT interval by the combination of Sotalol and Apomorphine. Parkinsonism [8A00] [38]
Methylscopolamine DM5VWOB Moderate Additive CNS depression effects by the combination of Sotalol and Methylscopolamine. Peptic ulcer [DA61] [39]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Sotalol and Macimorelin. Pituitary gland disorder [5A60-5A61] [56]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Sotalol and Lefamulin. Pneumonia [CA40] [57]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Sotalol and Degarelix. Prostate cancer [2C82] [38]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Sotalol and ABIRATERONE. Prostate cancer [2C82] [38]
Nilutamide DMFN07X Major Increased risk of prolong QT interval by the combination of Sotalol and Nilutamide. Prostate cancer [2C82] [38]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Sotalol and Enzalutamide. Prostate cancer [2C82] [38]
Flutamide DMK0O7U Major Increased risk of prolong QT interval by the combination of Sotalol and Flutamide. Prostate cancer [2C82] [38]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Sotalol and Relugolix. Prostate cancer [2C82] [38]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Sotalol and Bicalutamide. Prostate cancer [2C82] [38]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Sotalol and Terazosin. Prostate hyperplasia [GA90] [50]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Sotalol and Silodosin. Prostate hyperplasia [GA90] [50]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Sotalol and Levomepromazine. Psychotic disorder [6A20-6A25] [38]
Fluphenazine DMIT8LX Major Increased risk of prolong QT interval by the combination of Sotalol and Fluphenazine. Psychotic disorder [6A20-6A25] [38]
Triflupromazine DMKFQJP Major Increased risk of prolong QT interval by the combination of Sotalol and Triflupromazine. Psychotic disorder [6A20-6A25] [38]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Sotalol and Gatifloxacin. Respiratory infection [CA07-CA4Z] [42]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Sotalol and Quetiapine. Schizophrenia [6A20] [38]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Sotalol and Mesoridazine. Schizophrenia [6A20] [38]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Sotalol and Thioridazine. Schizophrenia [6A20] [38]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Sotalol and Aripiprazole. Schizophrenia [6A20] [44]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Sotalol and Iloperidone. Schizophrenia [6A20] [38]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Sotalol and Paliperidone. Schizophrenia [6A20] [38]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Sotalol and Haloperidol. Schizophrenia [6A20] [38]
Perphenazine DMA4MRX Major Increased risk of prolong QT interval by the combination of Sotalol and Perphenazine. Schizophrenia [6A20] [38]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Sotalol and Molindone. Schizophrenia [6A20] [44]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Sotalol and Thiothixene. Schizophrenia [6A20] [44]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Sotalol and Trifluoperazine. Schizophrenia [6A20] [38]
Risperidone DMN6DXL Major Increased risk of prolong QT interval by the combination of Sotalol and Risperidone. Schizophrenia [6A20] [38]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Sotalol and Amisulpride. Schizophrenia [6A20] [38]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Sotalol and Asenapine. Schizophrenia [6A20] [38]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Sotalol and Pimozide. Schizophrenia [6A20] [39]
Mepivacaine DMH2NMY Moderate Increased risk of bradycardia by the combination of Sotalol and Mepivacaine. Sensation disturbance [MB40] [47]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Sotalol and Vardenafil. Sexual dysfunction [HA00-HA01] [58]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Sotalol and LEE011. Solid tumour/cancer [2A00-2F9Z] [38]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Sotalol and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [38]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Sotalol and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [38]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Sotalol and Pitolisant. Somnolence [MG42] [38]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Sotalol and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [38]
Adenosine DMM2NSK Major Increased risk of ventricular arrhythmias by the combination of Sotalol and Adenosine. Supraventricular tachyarrhythmia [BC81] [59]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Sotalol and Lenvatinib. Thyroid cancer [2D10] [38]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Sotalol and Cabozantinib. Thyroid cancer [2D10] [38]
Pipecuronium DM5F84A Moderate Additive neuromuscular blocking effects by the combination of Sotalol and Pipecuronium. Tonus and reflex abnormality [MB47] [46]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Sotalol and Papaverine. Tonus and reflex abnormality [MB47] [60]
Doxacurium DMKE7L9 Moderate Additive neuromuscular blocking effects by the combination of Sotalol and Doxacurium. Tonus and reflex abnormality [MB47] [46]
Vecuronium DMP0UK2 Moderate Additive neuromuscular blocking effects by the combination of Sotalol and Vecuronium. Tonus and reflex abnormality [MB47] [46]
Cisatracurium DMUZPJ5 Moderate Additive cardiorespiratory depression effects by the combination of Sotalol and Cisatracurium. Tonus and reflex abnormality [MB47] [46]
Rocuronium DMY9BMK Moderate Additive neuromuscular blocking effects by the combination of Sotalol and Rocuronium. Tonus and reflex abnormality [MB47] [46]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Sotalol and Tacrolimus. Transplant rejection [NE84] [38]
Atropine DMEN6X7 Moderate Antagonize the effect of Sotalol when combined with Atropine. Unspecific substance harmful effect [NE6Z] [39]
Astemizole DM2HN6Q Major Increased risk of prolong QT interval by the combination of Sotalol and Astemizole. Vasomotor/allergic rhinitis [CA08] [61]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Sotalol and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [38]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Sotalol and Procainamide. Ventricular tachyarrhythmia [BC71] [38]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Sotalol and Propafenone. Ventricular tachyarrhythmia [BC71] [62]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Sotalol and Flecainide. Ventricular tachyarrhythmia [BC71] [38]
⏷ Show the Full List of 189 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Sotalol 120 mg tablet 120 mg Oral Tablet Oral
Sotalol 160 mg tablet 160 mg Oral Tablet Oral
Sotalol 80 mg tablet 80 mg Oral Tablet Oral
Sotalol 240 mg tablet 240 mg Oral Tablet Oral
Sotalol Hydrochloride 80mg tablet 80mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7297).
2 New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
3 BDDCS applied to over 900 drugs
4 Clinical pharmacokinetics of sotalol. Am J Cardiol. 1993 Aug 12;72(4):19A-26A.
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
8 Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
9 Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
10 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
11 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
12 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
13 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
15 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
16 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
17 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
18 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
19 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
20 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
21 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
22 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
23 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
24 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
25 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
26 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
27 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
28 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
29 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
30 Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
31 Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
32 Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
33 Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
34 Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
35 Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
36 beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
37 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
38 Canadian Pharmacists Association.
39 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
40 Cerner Multum, Inc. "Australian Product Information.".
41 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
42 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
43 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
44 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
45 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
46 Chapple DJ, Clark JS, Hughes R "Interaction between atracurium and drugs used in anaesthesia." Br J Anaesth 55 Suppl 1 (1983): s17-22. [PMID: 6688011]
47 Keidar S, Grenadier E, Palant A "Sinoatrial arrest due to lidocaine injection in sick sinus syndrome during amiodarone administration." Am Heart J 104 (1982): 1384-5. [PMID: 7148661]
48 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
49 Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
50 Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
51 Asgharnejad M, Powell R, Donn K, Danis M "The effect of cimetidine dose timing on oral propranolol kinetics in adults." Clin Pharmacol Ther 41 (1987): 203. [PMID: 3392231]
52 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
53 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
54 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
55 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
56 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
57 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
58 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
59 Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
60 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
61 Feroze H, Suri R, Silverman DI "Torsades de pointes from terfenadine and sotalol given in combination." Pacing Clin Electrophysiol 19 (1996): 1519-21. [PMID: 8904547]
62 Buss J, Neuss H, Bilgin Y, Schlepper M "Malignant ventricular tachyarrhythmias in association with propafenone treatment." Eur Heart J 6 (1985): 424-8. [PMID: 4043097]